Protocols›Metabolic, weight & GH›GH Optimisation
← Protocols
US-clinic · off-labelAthlete / performance · uptakeNo approved clinical use

GH Optimisation

Stack: CJC-1295 + Ipamorelin · gh-axis optimisation
"The default GH stack. The additive-GH biomarker data is fair; the body-composition and anti-ageing outcomes are oversold relative to what's been shown."
GoalGH-axis optimisation
Compounds2 · CJC-1295 + Ipamorelin
Humans exposed (est.)High — undocumented
StatusMHRA (UK): not licensed medicines here · FDA (US): not approved · the default clinic/community GH pairing
In this stack — snapshot; tap through for the full molecule file
Provenance & evidence layers — of the combination, not the parts
US-clinic
Where / who
Community / athlete and clinic use as tagged above.
Use status
The default GH stack in clinics and community.
Evidence it adds
Popularity / convention — not efficacy.
Basis: real-world uptake & convention — not trial data
US clinic · off-label compounding
Where / who
US functional-medicine, longevity & sports-medicine clinics — physician-prescribed via 503A/503B compounding pharmacies.
Track record
CJC-1295 / Ipamorelin: among the most commonly compounded peptides in US clinics until the Sept 2023 FDA Category 2 listing; removed from Category 2 Apr 2026, 503A Bulks List decision pending the PCAC meeting 23–24 Jul 2026.
Evidence it adds
Real-world clinical observation — physician-charted, supervised use. A genuine evidence tier, but observational: uncontrolled, unpublished, no registry, outside formal pharmacovigilance.
What it means
Off-label compounding under prescription — never an FDA-approved therapy. Removal from Category 2 is not approval.
Basis: US compounding-pharmacy practice · FDA Docket FDA-2025-N-6895
No approved clinical use
Clinical record
No country lists this exact combination as an approved therapy.
Human trials
No completed human trial of the combination. Biomarker rise fair; outcomes oversold.
Basis required for a clinical-use tag: none found — absence shown, not hidden
Why this combination

CJC-1295 (sustained) plus Ipamorelin (pulsatile) raises GH/IGF-1 additively — that part is reasonably supported. The leap to meaningful recomposition or longevity outcomes is not well evidenced.

Members only · the actionable depth
See exactly how it's run
Doses, cycle structure and what to monitor are part of membership. The provenance, evidence and exposure above are always free.
Start 30 days free →
No card needed · cancel anytime
Cycle shape — how it's typically structured, not a schedule to follow
Loading
build up
Maintenance
hold / taper
Off
stop / reassess
Convention from community use, not a prescription. Specific timing is part of membership.
What's worth monitoring

With limited or no human safety data for this combination, there is no established marker set to monitor against — which is a reason for more caution, not less. Baseline bloods and a clinician conversation matter here. General information, not medical advice.

Combination evidence
Real-world uptake High

The default GH stack in clinics and community.

Human efficacy Weak

Biomarker rise fair; outcomes oversold.

Clinical observation Observational

A decade-plus of physician-supervised, charted use — meaningful real-world signal, with no commonly-reported serious adverse-event pattern. But uncontrolled, unpublished, held in private charts (no registry) and outside formal pharmacovigilance. Not controlled evidence.

The honest ceiling

Solid on biomarkers, thin on outcomes.

Fast facts
Compounds

CJC-1295 · Ipamorelin

Humans exposed (est.)

High — undocumented.

UK strip

GREEN — research material